May 31, 2024
Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that updated results and subgroup analysis by presence of liver metastases of the phase I/II study of the EP4 antagonist CR6086 (vorbipiprant) with the anti-PD-1 antibody balstilimab (Agenus Inc, Nasdaq: AGEN) in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024.
The analysis indicates that vorbipiprant combined with an anti-PD-1 showed promising efficacy also in patients with liver metastases, a particularly challenging patient population since the presence of liver metastases is considered an immune resistance factor and is associated with poor outcomes of treatment with immune checkpoint inhibitors (ICIs).
Presentation Details
Abstract Title: Updated results and subgroup analysis by presence of liver metastases of a phase I/II study of the EP4 antagonist vorbipiprant with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Abstract Number: 3560
Presenting Author: Filippo Pietrantonio, MD, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Poster Board Number: 223
Presentation Session Date and Time: Saturday, June 01, 2024, 1:30 PM-4:30 PM CDT
The poster will be available to view in this website page following the ASCO congress.
About CR6086 (vorbipiprant)
CR6086 (vorbipiprant) is a novel targeted immunomodulator acting as an antagonist at the prostaglandin E2 (PGE2) receptor EP4 subtype. EP4 receptors have an important role in the altered immune response observed in autoimmune diseases. PGE2-EP4 signalling plays a major immunosuppressive role in the tumour microenvironment, and as such it favours cancer immune escape and tumour progression. Consistently, experimental evidence suggests that EP4 receptor antagonists may improve the response to immune checkpoint inhibitors (ICIs).
A Phase I/II clinical trial to evaluate the safety and efficacy of CR6086 in combination with the PD-1 inhibitor balstilimab in patients with pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer provided promising results presented at the European Society for Medical Oncology (ESMO) annual congress in 2023. Study expansion in other gastrointestinal tumors is ongoing.
About Rottapharm Biotech
Rottapharm Biotech is a research company dedicated to the discovery and development of innovative drugs. It is located in Monza (Italy). The company expertise in research and development includes medicinal/computational chemistry for small molecules, development of biologics and advanced therapies, new targets validation, pharmacological and pharmacokinetic characterization of new drug candidates, original formulations, and design of innovative clinical trials. The company strategy is to develop its own pipeline independently and then seek partnerships with pharmaceutical companies, as well as investing in alliances on innovative projects of other biotech companies or university spin-offs.
Rottapharm Biotech Contact
Federica Girolami, Business Development Director
Tel. +39 346 4131428
federica.girolami@rottapharmbiotech.com
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that
may be important to investors will be routinely posted on our website and social media channels.
About balstilimab
Balstilimab (Agenus, Inc.) is an investigational monoclonal antibody inhibitor of programmed cell death 1 (PD-1) protein. It has been evaluated in >900 patients to date and has demonstrated strong clinical activity and an excellent safety profile in several tumour types.
Agenus Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding clinical development and regulatory plans and timelines, anticipated corporate milestones, new clinical data and program updates to be presented. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Agenus Inc. Media
781-674-4784
communications@agenusbio.com